Physician profile
Arin Jackson
NPI 1366822728
$4,670.60
in general payments reported to CMS, 2019-2025
42 companies · $967 in 2025
The $967 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.40 · 2022: $326 · 2023: $1,547 · 2024: $1,801 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,315.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $358.19 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $354.36 | 2023-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $354.19 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $333.36 | 2022-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $309.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $280.95 | 2023-2025 | Calquence, Enhertu, Imfinzi |
| Celgene Corporation | $235.03 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Abbvie INC. | $194.47 | 2024-2025 | |
| Pfizer INC. | $171.27 | 2023-2025 | |
| Kite Pharma, INC. | $169.32 | 2023-2025 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $168.55 | 2023-2025 | Fruzaqla, Vonvendi |
| Merck Sharp & Dohme LLC | $154.76 | 2023-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $134.09 | 2021-2025 | Ojjaara, Shingrix, Zejula |
| Beigene USA, INC. | $117.87 | 2022-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $108.94 | 2023 | Imbruvica |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $98.74 | 2024-2025 | |
| Janssen Biotech, INC. | $92.33 | 2022-2025 | Rybrevant, Talvey, Darzalex |
| Eisai INC. | $92.06 | 2022-2024 | |
| Astellas Pharma US INC | $75.74 | 2023-2024 | Padcev |
| Aveo Pharmaceuticals, INC. | $69.96 | 2023-2025 | Fotivda |
| Mirati Therapeutics, INC. | $63.60 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $58.17 | 2023-2025 | Orgovyx |
| Karyopharm Therapeutics INC. | $54.63 | 2021-2024 | Xpovio |
| Lilly USA, LLC | $50.83 | 2022-2024 | Jaypirca, Retevmo, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $47.06 | 2022-2025 | |
| Seagen INC. | $46.65 | 2023 | Padcev, Tukysa |
| Alexion Pharmaceuticals, INC. | $43.27 | 2023-2024 | Ultomiris |
| Amgen INC. | $41.81 | 2022-2023 | Blincyto, Kyprolis |
| Sobi, INC | $40.92 | 2023 | |
| Pharmacosmos Therapeutics INC. | $39.05 | 2024 | Cosela |
| Puma Biotechnology, INC. | $38.39 | 2024-2025 | |
| Legend Biotech USA INC. | $36.86 | 2025 | Carvykti |
| Stemline Therapeutics INC. | $32.74 | 2023 | Orserdu |
| Iovance Biotherapeutics, INC. | $32.29 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $30.84 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.69 | 2024 | Gilotrif |
| Tersera Therapeutics LLC | $22.81 | 2024 | Zoladex |
| Immunocore Limited | $22.07 | 2024 | Kimmtrak |
| Geron Corporation | $19.87 | 2025 | Rytelo |
| Morphosys, US INC. | $19.34 | 2023 | Monjuvi |
| Emd Serono, INC. | $16.67 | 2024 | |
| Apellis Pharmaceuticals, INC. | $13.47 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arin Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.